Clinical trial
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in…
NCT00077428 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00077428 |
|---|---|
| Title | Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck |
| Official title | Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | SWOG Cancer Research Network |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Adenoid Cystic Carcinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer |
| Intervention type | Drug, Other |
| Interventions | bortezomib, doxorubicin hydrochloride, laboratory biomarker analysis |
| Enrollment | 37 |
| Start date | Jun 1, 2004 |
| Primary completion | Jun 1, 2007 |
| First posted | Feb 12, 2004 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: